Dr. Sunil Patel Joins Allgenesis’ Scientific Advisory Board

Allgenesis Receives Notice of Grant of Japanese Patent for anti-VEGF/Disintegrin Fusion Protein
Allgenesis Signs Deal to In-License a Clinical Stage Drug Candidate for Dry Eye Disease
Show all

Taipei, Taiwan/ February 20th, 2020

Dr. Sunil Patel, MD., Ph.D.

Allgenesis is honored to welcome Dr. Sunil Patel to our Scientific Advisory Board (SAB), which is led by Dr. Larry Wheeler. Dr. Patel is certified by the American Board of Ophthalmology and has been a practicing Vitreoretinal Surgeon for the past 20+ years in the west Texas areas. He is currently the Managing Partner at Ophthalmology Specialist of Texas, PLLC and Abilene Surgery Center; the President of Integrated Clinical Research, LLC; and a Staff Investigator for Strategic Clinical Research Group. Dr. Patel has participated as a Principal Investigator for numerous clinical trials of new drugs for the treatment of wet Age-related Macular Degeneration and Diabetic Macular Edema.

“I am pleased to have Dr. Patel join our SAB. His background in immunology, and his wealth of experience in the treatment of retinal diseases will be very instrumental to our efforts in advancing the development of our bi-specific retinal drug AG-73305”, said Dr. Madhu Cherukury, the CEO of Allgenesis. “We are excited to have him onboard as part of the Allgenesis team!”

About Allgenesis

Allgenesis is a clinical stage biopharmaceutical company based in Taipei, Taiwan. The company is focused on research and development of novel medicines for the treatment of eye diseases. Current projects in the pipeline include AG-73305, a potential blockbuster drug for the treatment of DME, wAMD, and other retinal diseases, AG-86893 for pterygium, and AG-67650 for wAMD.

About AG-73305

AG-73305 is a first-in-class molecule specifically designed for the treatment of DME, wAMD, and other retinal diseases. AG-73305 is a single fusion protein that simultaneously binds with high potency and specificity to VEGF and integrins, which are known to be involved in retinal diseases. AG-73305 has the potential to treat anti-VEGF responders and non-responders.